Gilteritinib fails to improve overall survival in newly diagnosed FLT3 mutation-positive acute myeloid leukaemia

A planned interim analysis of the Phase III LACEWING RCT which evaluated gilteritinib plus azacitidine, vs azacitidine alone, in 250 newly diagnosed AML pts ineligible for first-line intensive induction chemotherapy, reported failure to meet primary endpoint of overall survival.

Source:

Biospace Inc.